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       TLS is an oncological emergency and 
a major cause of morbidity and mortality 
in cancer patients in the United States 
and worldwide [1]. TLS causes cell lysis 
and the release of massive amounts of 
potassium, phosphate, and nucleic acid 
into the general circulation [5].  This 
causes characteristic electrolyte 
abnormalities within the blood that 
leads to impaired renal function, cardiac 
dysrhythmias, end-organ failure, and 
death if not treated [5]. The key to 
managing TLS is prevention, along with 
prompt recognition of symptoms, 
immediate intervention, and escalation 
of care when necessary 
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TLS is a rapidly developing 
oncological emergency characterized by 
a number of metabolic abnormalities 
including, hyperuricemia, 
hyperphosphatemia, hyperkalemia, and 
hypocalcemia [2]. TLS is asymptomatic 
initially, but has the ability to affect the 
renal, gastrointestinal, cardiac, and 
neuromuscular systems [10].  
Hyperuricemia contributes to the 
development of acute renal failure. Signs 
and symptoms include [6]: 
• Flank pain  
• Gross hematuria 
• Cloudy urine 
• Oliguria 
• Lethergy 
Hyperkalemia and hypocalcemia may 
cause gastrointestinal complications 
such as [6]: 
• Nausea 
• Vomiting 
• Diarrhea 
• Intestinal cramping 
Hyperkalemia will cause 
electrocardiogram (ECG)  and 
neuromuscular changes these include 
[6]: 
• Atrial tachycardia 
• Irregular heart rhythms 
• Life-threatening arrhythmias 
• Neuromuscular irritability 
• Muscle weakness 
• Paralysis 
Hypocalcemia also affects the 
neuromuscular system and can  
manifest as [6]: 
• Neuromuscular excitability 
• Seizures 
• Tetany 
 
 
 
           The key in TLS is to recognize 
which patients are at risk and 
implementing preventative measures 
before the initiation of therapy [10]. 
Patients at highest risk of developing TLS 
include [10] 
• Those with rapidly multiplying 
malignant cells 
• The elderly 
• Those dehydrated at the start of 
therapy 
• Those with pre-existing renal 
disease 
However, any patient receiving 
oncological therapies may develop TLS. 
Nurses administering chemotherapy 
should be knowledgeable about key 
abnormal laboratory values  and clinical 
symptoms of: 
• Hyperkalemia 
• Hyperphosphatemia 
• Hypocalcemia   
 
         Those at high risk should be placed 
on continuous cardiac monitoring [4]. 
Electrolytes, renal function, and uric acid 
should be measured every 4-6 hours for 
high-risk individuals, and every 8-12 
hours for those at intermediate to low 
risk [4]. Recognizing signs and 
symptoms of acute renal failure is of 
paramount importance as escalation of 
treatment modalities may be necessary 
and life saving in these individuals. 
Practitioners should be on the look out 
for signs of 
[8]: 
• Oliguria, 
• Fluid overload 
• Hypertension 
• Pulmonary edema  
In addition, blood urea nitrogen (BUN) 
and creatinine should be monitored 
daily[8].  
        Patient and family education is also 
important. Patients should be educated 
about complications of chemotherapy 
and TLS if they are at risk. It is important 
for the nurse to review home 
medications, especially if the patient is 
pre-medicating at home with allopurinol 
or rasburicase before treatment. 
Information of correct medication 
administration may be key in preventing 
complications associated with TLS. 
Keeping the patient and family informed 
also allows the patients’ and family 
members to feel more in control and take 
a more active role in their treatment.  
 
 
     Patients with oncological conditions 
are at an increased risk of developing a 
wide variety of complications from 
chemotherapy that they would not 
otherwise be exposed too. One such life 
threatening complication is tumor lysis 
syndrome, which is an oncology 
emergency that frequently lands patients 
in the intensive care unit. Tumor lysis 
syndrome (TLS) occurs most frequently 
after the initiation of chemotherapy or 
other chemotoxic drugs during the 
patients’ treatment course [8]. It causes 
faster than normal tumor cell breakdown 
and release of intracellular contents into 
the general circulation. [8]. This leads to 
a very predictable development of 
electrolyte imbalances to take place 
within the body, which if not treated can 
lead to end-organ damage as well as fatal 
cardiac dysrhythmias [8]. While TLS is 
fairly uncommon, there are specific 
factors that place some individuals at a 
higher risk of developing TLS then 
others. These include large tumor size, 
tumors with rapid cell division, and 
hematological cancers such as leukemia 
[3]. In addition, TLS can progress 
extremely quickly and has a high rate of 
morbidity and mortality [8]. It is 
important that nurses and physicians are 
educated and on the look out for TLS in 
high-risk individuals and initiate 
prophylactic treatment if indicated. Also, 
prompt recognition of TLS and initiation 
of treatment modalities is key to 
preventing end-organ damage and 
possibly death.  
      In oncology specific intensive care 
units, such as the medical intensive care 
unit at The James Cancer Hospital in 
Columbus, Ohio, TLS is one of the most 
common reasons for patients to receive 
continuous renal replacement therapy 
(CRRT) after sepsis. The purpose of this 
poster is to provide information to 
nurses on general oncology floors so that 
they are able to recognize the signs and 
symptoms of TLS early, in the hopes that 
early identification and treatment will 
improve patient outcomes and decrease 
the number of patients with acute kidney 
injuries necessitating the need for CRRT.  
   TLS occurs as the result of tumor cell 
breakdown, usually after exposure to 
chemotherapy or chemotoxic drugs. 
When cancer cells are destroyed they 
release massive amounts of intracellular 
contents into the extracellular space, 
which cause characteristic electrolyte 
abnormalities such as: hyperuricemia, 
hyperphosphatemia, hyperkalemia, and 
hypocalcaemia  [2]. These imbalances 
occur in part due to the fact that cancer 
cells have an abnormally high amount of 
potassium, phosphorus, and nucleic acid 
contained within the cell  [6]. 
Hyperkalemia and hyperphosphatemia 
normally results 12-24 hours after 
chemotherapy is initiated [8]. 
Hyperkalemia results from the high levels 
of potassium that spills into the 
extracellular space from the lysed 
malignant cells, as well as from a 
disruption in the sodium/potassium 
adenosine triphosphatase pump which 
lowers the threshold for potassium 
exchange into the extracellular space [8]. 
This potentiates the effects of 
hyperkalemia by causing additional 
potassium to leak from uninjured 
cancerous cells into the extracellular 
space even before cell lysis has occurred 
[8]. Hypocalcemia results when 
extracellular calcium binds to the 
elevated phosphorus circulating in the 
bloodstream, which in turn leads to 
decreased serum calcium [6].  
      Hyperuricemia generally occurs 48-
72 hours after initiation of treatment as 
the liver converts the excess nucleic acids 
into uric acid [8]. Under normal 
circumstances small amounts of uric acid 
are excreted by the kidneys, while the 
majority of uric acid is reused by the 
body through the salvage pathways [8]. 
Initially, the kidneys will try to 
compensate for the excess uric acid in the 
blood stream by increasing urine output, 
but as intravascular fluid volume is 
depleted uric acid crystals build up in the 
renal tubules causing intrarenal 
crystallization [8]. Uric acid also disrupts 
the renin-angiotensin aldosterone system 
by causing renal vasoconstriction, 
impaired auto-regulation, decreased 
renal blood flow, oxidation, and 
inflammation [4]. These electrolyte 
abnormalities produce clinical toxic 
effects which may include renal 
insufficiency, cardiac dysrhythmias, 
seizures, and multi-organ failure leading 
to death if not treated [4].  
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However, while allopurinol prevents 
the formation of new uric acid from 
forming, existing uric acid in the body must 
still be excreted [8]. It may take the body 
up to two days to decrease pre-existing uric 
acid levels, which may be enough time to 
cause nephropathy in some individuals [4].  
In addition, xanthine, the end by-
product  of allopurinol, may accumulate in 
the renal tubules causing xanthine 
nephropathy [4]. In contrast, Urate oxidase 
(rasburicase) works by breaking down uric 
acid into a more soluble compound the 
body can execrate called allantoin[4]. This 
prevents the formation of xanthine and 
secondary accumulation in the renal 
tubules and decreases the risk of 
nephropathy [4].   
Patients should also be pre-treated 
with allopurinol or rasburicase therapy. 
Both therapies aim to control uric acid 
levels by interfering with purine 
catabolism, in an effort to prevent uric 
acid crystal formation in the renal tubules 
and preserve kidney function [8]. 
Allopurinol is a pharmacological 
medication that works by inhibiting the 
enzyme xanthine oxidase, which blocks 
the conversion of enzymes that form uric 
acid [5].  
However, the uricase enzyme that breaks 
down uric acid in rasburicase is not 
normally found in humans. Administration 
of rasburicase in patients has been known 
to cause allergic reactions, at times leading 
to anaphylaxis [8]. In addition, high costs to 
institutions and lack of insurance coverage 
limits the use of rasburicase in practice [8]. 
Patients who have a pre-existing uric acid 
level of >7.5mg/dL would benefit most from 
rasburicase therapy and should be 
considered for use in contrast to allopurinol 
[8]. 
 See Reference list [12] 
Management of other dangerous 
electrolyte abnormalities is important as 
well, specifically hyperkalemia, which can 
cause lethal cardiac dysrhythmias if left 
untreated. Administration of 50% 
dextrose in water and 10 units of regular 
insulin IV should be given for immediate 
treatment for potassium levels > 6mEq 
[8]. This shifts excess potassium into the 
intracellular space. For milder cases and 
longer term control sodium polystyrene 
sulfonate (kayexalate) can be given to 
help bind with excess potassium in the 
gut as well as loop diuretics to promote 
excretion of potassium through the 
kidneys[8].  
It is also important to treat high 
phosphorus levels in the blood. If 
phosphorus levels are above 7mg/dL 
then 20% dextrose in water should be 
given with insulin [8]. Once phosphorus 
levels fall below 7mg/dL then oral 
phosphate binder such as aluminum 
hydroxide may be given, which works by 
binding with free phosphate in the 
intestines to prevent absorption [8]. If 
phosphorus levels are corrected then 
hypocalcemia should inversely correct 
itself. Correcting hypocalcemia is 
discouraged as it can potentiate the 
development of calcium deposits in 
tissues [8]. Replacement should only be 
given to individuals who are experiencing 
signs and symptoms of neuromuscular 
excitability [8].  
Despite prophylactic treatment many 
patients’ kidneys may not be able to keep 
up with the increased workload 
demanded of them. Dialysis should be 
considered in patients exhibiting 
symptoms of oliguria, fluid overload, or 
signs and symptoms related to abnormal 
electrolyte levels [8]. Intermittent 
dialysis or continuous renal replacement 
therapy (CRRT) may be used to help filter 
the blood and remove excess byproducts. 
Generally, CRRT is recommended in 
patients with TLS because the filters use 
larger bore sizes, which allows for  more 
rapid clearance of molecules, in 
particular it is more effective in removing 
phosphorus from the blood and does not 
have the rebound effect of hyperkalemia 
that conventional intermittent dialysis 
does [4]. The goal of dialysis therapy is to 
correct the underlying electrolyte 
imbalances and restore renal function.  
 
 
     Understanding the pathophysiology of 
TLS allows practitioners to put measures 
in place to prevent complications 
associated with cancer treatments in 
moderate to high risk individuals. All 
patients who are high risk should 
receive intravenous hydration beginning 
2 days before treatment and continuing 
for 2-3 days after chemotherapy [3]. 
Fluids are administered at a rate of 2 to 
3L/day with a goal urine output of 100-
200 mL/hour [8].  This helps maintain 
renal perfusion and minimize uric acid 
crystal formation in renal tubules [4]. 
Nurses should pay particular attention 
to urine output; if output remains low 
despite aggressive fluids then loop 
diuretics are recommended to achieve 
target urine output [4].  
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